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ABSTRACT 
 
Attenuation of postprandial glycemia is hypothesized to reduce the risk of 
progression from impaired glucose tolerance to diabetes.  It is also thought to reduce the 
number of complications associated with diabetes.  S. oblonga extract has been shown to 
reduce postprandial glycemia when it is fed in addition to a liquid nutritional supplement 
containing mainly maltodextrin.  No studies have been done, however, using S. oblonga 
extract on a solid meal.  The purpose of this study was to measure the effects of S. 
oblonga extract on the postprandial glycemic and lactate responses along with the 
perceived gastrointestinal, satiety, and flatulence symptoms severity following a solid, 
high starch meal.  Fourteen subjects (8 males, 6 females) ate two test meals after an 
overnight fast following a standardized dinner.  The meals consisted of 112 g durum 
spaghetti noodles, one cup (8 oz.) of Meijer meatless spaghetti sauce, and one cup (8 oz.) 
of unsweetened, caffeine-free tea.  In the treatment meal, the tea also contained 480 mg 
of S. oblonga extract.  The subjects had their glycemic responses to the meals measured 
through two hours postprandial.  The subjects then ate a standardized lunch and reported 
perceived satiety, gastrointestinal distress, and frequency of flatulence while fasting for 
an additional five hours.  The serum glucose positive incremental area under the curve 
(AUC) response was reduced by 25% (P = 0.022) and the serum lactate AUC response 
was reduced by 29% (P = 0.033) in the treatment meal compared with the control meal.  
The serum glucose baseline-adjusted peak was reduced by 27% (P < 0.001) and the 
serum glucose excursion was reduced by 23% (P = 0.002) in the treatment meal 
compared with the control meal.  Also, the total number of gas passages for hours 0-8 
increased from 7.29 ± 1.76 in the control to 26.4 ± 4.59 in the treatment (P = 0.001) 
indicating the alpha-glucosidase inhibitory effects of S. oblonga.  In summary, S. oblonga 
extract effectively lowered the postprandial glucose response to a high starch meal, 
consistent with previous studies on this herb.  The extract may have value in the 
management of blood glucose for persons with diabetes.  The development of mild to 
moderate flatulence is a limitation for the use of this herbal extract.  More studies are 
needed to develop ways to improve gastrointestinal tolerance.  
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INTRODUCTION 
 
Overview of Diabetes Mellitus 
 
 Approximately 18.2 million people (6.3% of the population) in the United States 
have Diabetes Mellitus and its prevalence is on the rise (1, 2).  Diabetes is defined as 
having a fasting blood glucose (FBG) of > 126 mg/dl and/or a glucose response of ≥ 200 
mg/dl to a two hour, 75 g oral glucose tolerance test (OGTT, 3).  Such glucose 
intolerance is due to defects in insulin production, insulin action, or both (1).  Type 1 
Diabetes Mellitus (T1DM) results from an autoimmune response to the body’s own 
pancreatic beta cells, where insulin production occurs, and is thus treated with 
administration of insulin (4).  T1DM occurs in approximately 10% of all diabetes cases.  
The other 90% of cases are of Type 2 Diabetes Mellitus (T2DM).  T2DM results from a 
combination of insulin resistance and an inability of pancreatic beta cells to secrete 
enough insulin in response to a rise in plasma glucose concentrations (4).  T2DM is 
treated using weight reduction, exercise, and dietary modification programs along with 
oral medications.  The estimated cost of caring for diabetes was approximately $132 
billion in the US in 2002, including $17.5 billion in outpatient medications (5). 
 Chronic hyperglycemia induced by diabetes is associated with higher risks of 
strokes, coronary heart disease, peripheral vascular disease, dyslipidemia, hypertension, 
and obesity.  This chronic hyperglycemia is also associated with damage to and failure of 
the eyes, kidneys, nerves, heart, and blood vessels (3).  These abnormalities occur due to 
the accumulation of glucose metabolites and the glycosylation of certain proteins, 
including hemoglobin (4).  Elevated glycosylated hemoglobin (HbA1c) levels > 7% are 
associated with a glucose response of ≥ 228 mg/dl during an OGTT (6).   
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Treatment of Diabetes Mellitus
 Treatment for T2DM aims to reduce the postprandial blood glucose response and 
HbA1c levels in the blood.  Low Glycemic Index (GI) diets have been shown to improve 
blood-glucose control in patients with T1DM and T2DM (7).  Other methods include: 
• increasing insulin output from the pancreatic beta cells using 
sulfonylurea drugs, such as glimepiride, or herbs, such as 
fenugreek (8, 9) 
• decreasing hepatic glucose output using biguanide drugs, such as 
metformin (8) 
• increasing insulin sensitivity using thiazolidinedione drugs, such as 
pioglitazone, or supplements, such as chromium (8, 10) 
• decreasing formation of glycylated proteins using acetylating 
agents and antioxidants, such as the herb ginseng (11) 
• decreasing stomach emptying rates using viscous and soluble fiber, 
such as guar gum (12) 
• decreasing the amount of carbohydrate absorbed from the small 
intestine using alpha-glucosidase inhibitor drugs, such as acarbose, 
and herbs, such as Salacia oblonga (8, 13) 
• increasing hepatic glucose uptake using fructose (14) 
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Alpha-Glucosidase Inhibitors
 Chiasson et al. measured the effects of chronic use of the alpha-glucosidase 
inhibitor acarbose over a 3 year period; Refer to Figure 1 (15).  Subjects with impaired 
glucose tolerance were allocated into two groups: 714 were placed in the acarbose group 
and 715 were placed in the placebo group.  The acarbose and placebo were taken 3 times 
a day for 3.3 years by the respective groups, immediately before beginning consumption 
of a meal.  Chiasson et al. found a reduced risk of progression from impaired glucose 
tolerance to diabetes of 25% in the acarbose group compared with the placebo group.  
This reduction in risk was hypothesized to occur because of the decreased postprandial 
glucose response due to the blocked alpha-glucosidase enzyme by acarbose.  Chiasson et 
al. also hypothesized that the increased reversion to normal glucose tolerance in the 
acarbose group was due to the decreased postprandial glucose response as well. 
 
                              
Figure 1: Structure of Acarbose.  Acarbose mimics the oligosaccharide substrate and 
binds to alpha-glucosidase with a greater binding affinity than oligosaccharides (16). 
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 Hanefeld et al. conducted a meta-analysis of seven randomized, placebo-
controlled acarbose studies with a minimum duration of 52 weeks (17).  All patients in 
these studies had diabetes, with the vast majority being type 2 diabetics.  Under acarbose 
treatment, a significant prolongation of time in which patients remained free of any newly 
diagnosed cardiovascular events occurred compared with patients under the placebo 
treatment.  Additionally, a 64% relative risk reduction for myocardial infarctions was 
observed for the acarbose treatment group.  Long term glycemic control was observed in 
the acarbose treatment group compared with the placebo group, with a significant 
reduction in HbA1c levels, fasting and postprandial blood glucose levels in acarbose 
patients.  Patients in the acarbose group also demonstrated lowered plasma triglycerides 
levels, body weight, BMI, systolic blood pressure, reduced insulin levels, and increased 
insulin sensitivity secondary to reduced postprandial glycemia (17).    
 
LITERATURE REVIEW 
Extracts from the roots and stems of Salacia oblonga, a woody climbing plant that 
grows in parts of India and Sri Lanka, have been shown to have alpha-glucosidase 
inhibitory activity in vitro and may be useful in the prevention and/or treatment of 
diabetes (18-22).  Two thiosugars isolated from S. oblonga extract, salacinol and 
kotalanol, have inhibitory effects, in vitro, against maltase, isomaltase, and sucrase, with 
the inhibitory effect against sucrase being more potent than the prescription alpha-
glucosidase inhibitors acarbose and voglibiose that are used in the treatment of diabetes 
(23).  Through the reduction of the enzymatic breakdown of  di-, tri-, and 
oligosaccharides by alpha-glucosidase, carbohydrate absorption is decreased, attenuating 
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the postprandial glycemic response.  The undigested di-, tri-, and oligosaccharides pass 
through the small intestine into the colon where they are digested by the colonic 
microflora producing gaseous byproducts, demonstrated by the increased breath 
hydrogen responses in Heacock et al (24).  Lowering of postprandial glycemia by S. 
oblonga extract has been observed in rats fed either maltose or sucrose, but not glucose, 
which is consistent with its alpha-glucosidase inhibitory effect in the small intestine (22).   
Salacinol contains a zwitterion consisting of a sulfonium ion with an internal 
sulfate counterion; Refer to Figure 2 (19).  It is hypothesized that the permanent positive 
charge on the sulfur atom in the 1,4-anhydro-4-thio-D-arabinitol moiety binds to alpha-
glucosidase through mimicry of the shape and charge of the oxacarbenium-ion 
intermediate in the hydrolysis reaction mediated by alpha-glucosidase; Refer to Figure 3 
(16).  Kotalanol contains the same 1,4-anhydro-4-thio-D-arabinitol moiety and is 
believed to work via the same mechanism as salacinol (Figure 1). 
 
 
Figure 2: Structure of Salacinol and Kotalanol.  The permanent positive charge residing 
on the sulfur atom in the 1,4-anhydro-4-thio-D-arabinitol moiety may be resposible for 
the alpha-glucosidase inhibition in vitro (25). 
 
 8
 Figure 3: Mechanism of alpha-glucosidase hydrolysis of oligosaccharides into free 
monosaccharides.  S. oblonga extract mimics the oxacarbenium-ion intermediate formed 
after step one of the reaction (26). 
 
 
                 Heacock et al. and Collene et al. have demonstrated that S. oblonga extract 
reduces postprandial glycemia and insulinemia when it is fed in addition to a liquid 
nutritional supplement containing mainly maltodextrin (61% of available carbohydrate) 
as the carbohydrate source (13, 27).  Heacock et al. measured the effects of varying doses 
of S. oblonga extract on postprandial glycemia in 39 healthy subjects (13).  Subjects were 
fed a test beverage containing 49.5g maltodextrin with and without 1000 mg of S. 
oblonga extract.  Serum glucose AUC was reduced by 23% and serum insulin AUC was 
reduced by 29% to the test beverage containing 1000 mg of extract compared with the 
test beverage alone.  An increased breath hydrogen response was also measured with the 
1000 mg treatment, indicating that carbohydrate malabsorption was at least partially 
responsible for the decreased glycemic response.  These results are consistent with 
previous studies measuring postprandial glycemia using acarbose (13).   
Collene et al. measured S. oblonga extract and free amino acids on postprandial 
glycemia in 43 healthy subjects (27).  This study found a 24% decrease in postprandial 
AUC glycemic response to a test beverage containing 82 g carbohydrate, 20 g protein, 
and 14 g fat with 1000 mg S. oblonga extract compared with the test beverage alone.  
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Serum insulin response to the test beverage was also lower with the addition of S. 
oblonga. Extract fed with the beverage in addition to 3.5 g of phenylalanine and leucine 
led to a 27% decrease in postprandial AUC glycemia compared with the test beverage 
alone (27).  Serum insulin response to the extract plus free amino acid meal was 
insignificantly lower compared with the serum insulin response to the control (27). 
Other studies have determined that chronic use (daily use for 2-3 months) of 
Salacia herbs might also improve long-term glucose control (28-30).  Jayawardena et al. 
tested S. reticulata use for 3 months on 51 subjects with type 2 diabetes mellitus.  S. 
reticulata also contains the alpha-glucosidase inhibitors salacinol and kotalanol (30).  
Subjects in this study consumed Kothala Himbutu tea daily for six months: three months 
of which contained S. reticulata extract and three months of which did not (30).  A 
decrease in HbA1c was observed in patients after the S. reticulata treatment than after the 
placebo treatment (6.29 +/- 1.02 in treatment vs. 6.65 +/- 1.04 in placebo).  Jayawardena 
et al. also reported no significant abnormalities in liver or renal function after treatment 
with S. reticulata, with the main adverse effect reported being loose stools (30). 
The safety profile of Salacia herbs has been studied in laboratory animals.  Wolf 
and Weisbrode measured the effects of S. oblonga extract in a two week trial using 
Sprague-Dawley rats at a dose approximately 10 times higher than used in human trials 
(31).  The rats fed the extract showed significantly reduced weight gain and relative liver 
and spleen weights; however no significant histopathological changes in hepatic or renal 
functions occurred.  Shimoda et al. also showed no adverse effects on food intake, body 
weight, blood chemistries, organ weights, or histopathological findings on rats fed S. 
reticulata at doses up to 1000 mg/kg for 13 weeks of continuous intake (32).  Results 
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observed by Ratnasooriya et al., however, show that S. reticulata fed to Wistar rats 
during early to mid-pregnancy was associated with increased post-implantations losses, 
reduced birth weight of the pups, reduced fetal survival ratio, and reduced viability ratio 
at a dose 170 times greater than doses fed previously in humans (33). 
 
OBJECTIVE OF STUDY 
While the effects on postprandial glycemia have been observed with carbohydrate 
test beverages, the effects of S. oblonga extract have not yet been evaluated in the context 
of a solid meal (13, 27).  The method for delivering the carbohydrate load in postprandial 
glycemia studies is important for several reasons.  The anti-hyperglycemic effects of 
acarbose are more apparent when the drug is given with a solid meal versus a liquid meal 
(34).  This increased effectiveness of acarbose occurred in both healthy subjects and 
subjects with diabetes, although the effect was somewhat more pronounced in healthy 
subjects.  The likely explanation for these findings is that liquid meals empty from the 
stomach too rapidly, allowing the carbohydrate from the meal to reach the intestine 
before the medication can become active.  Additionally, 2-hour glucose tolerance tests 
performed with a standardized solid meal may result in less variability in postprandial 
glucose responses compared with a glucose solution due to the increased gastric-
emptying time as well (21).  The objective of this study is to evaluate the effects of S. 
oblonga extract on the postprandial glycemic response to a high starch, solid meal along 
with its effects on the postprandial lactate response and on perceived gastrointestinal 
tolerance, satiety and flatulence. 
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HYPOTHESES 
It is anticipated that there will be a reduction in the postprandial glycemic AUC 
response to the high starch, solid meal using S. oblonga extract compared with the control 
meal.  A similar reduction in the postprandial lactate AUC response is also anticipated 
using the S. oblonga extract.  Additionally, it is anticipated that subjects will experience 
increased flatulence to the S. oblonga extract meal compared with the control meal, 
consistent to the increased breath hydrogen AUC response to S. oblonga extract in 
previous studies.  Fermentation by colonic bacteria is the only significant source of 
hydrogen in the breath (13, 27).  Lastly, it is anticipated that an increased feeling of 
bloating will occur with the S. oblonga extract while there will be no difference in 
nausea, headache, or abdominal cramping between the two treatments.  Similar symptom 
ratings occurred in the study by Heacock et al.   
 
METHODS 
Subjects
Subjects were healthy adults and were enrolled in the study based on the 
following criteria: 
1) Subject was male or a non-pregnant female between the ages of 18-45 
of any race.  Screening for pregnancy via a commercially available 
urine test (Fact Plus Select, Abbott Laboratories, Chicago, IL) was 
conducted on all females who met other eligibility criteria.  Pregnant 
women were excluded due to effects of pregnancy on glucose 
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metabolism and the unknown effects that S. oblonga extract might 
have on the developing fetus. 
2) Female subjects on oral contraceptives were taking these agents for at 
least 3 months prior to the study and were consistently using the 
medication throughout the study. 
3) Subject was willing to complete all necessary study questionnaires and 
agreed to keep notes and records if required. 
4) Subject was interested in participating in the study after: a) being fully 
informed about the experimental treatments and the trial procedures, b) 
reviewing the study methodology, and c) signing a subject consent 
form. 
5) Subject had a body mass index (BMI) between 20 and 28 OR subject 
had a BMI > 28 and ≤ 30 and had a waist circumference ≤ 35 inches if 
female or ≤ 40 inches if male.  BMI = weight (kg)/ height² (m²) (35) 
6) Subject did not have diabetes mellitus or glucose intolerance.  Fasting 
(at least 10 hrs.) plasma glucose level was < 100 mg/dl (36).  A 
capillary finger-stick blood sample (1 drop) was obtained from the 
subject at screening for measurement of plasma glucose using a 
portable blood glucose monitor (Accucheck Advantage, Roche, Inc., 
Indianapolis, IN). 
7) Subject stated that he/she is free from active metabolic or 
gastrointestinal diseases which may interfere with nutrient absorption, 
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distribution, metabolism, or excretion and that the subject has no 
known food allergies. 
8) Subject had not had a recent infection requiring medication or 
hospitalization; surgery; corticosteroid treatment in the last 3 months; 
or taken antibiotics in the last three weeks. 
9) Subject was willing to consume a high carbohydrate diet (at least 150 
g daily) for the three days prior to the test (37). 
10) Subject was willing to fast at least 10 hours prior to the test.  During 
fasting, the subject consumed only water. 
11) Subject abstained from vigorous exercise 24 hours prior to testing, 
performing only usual activities, and minimized activity during the 
test. 
12) Subject was not taking daily medications (e.g., acetaminophen, 
salicylates, diuretics, etc.) that would interfere with nutrient 
absorption, metabolism, excretion, or gastric motility. 
13) Subject was not taking any dietary supplements that would affect 
serum glucose levels or glucose metabolism. 
14) Subject did not have a history of drug or alcohol abuse in the previous 
six months. 
15) Subject did not have an active weight loss of > 5 kg, intended or 
unintended, in the previous three months. 
 
 
 14
Sample Size 
The sample for glycemic index studies typically consists of approximately 10 
healthy adults (38).  A power analysis was conducted using data from a previous study 
(Power Analysis Sample Size module, Number Cruncher Statistical System 2001, NCSS 
Computing, Kaysville, UT).  Using a difference of 0.9 mmol/L in baseline-adjusted peak 
serum glucose, a standard deviation of 1.1 mmol/L, and an alpha level of 0.05, a total of 
14 subjects were required for 80% power in a crossover type of design (each subject 
serving as his/her own control).  Thus, our  sample size estimate was 14 subjects (8 males, 
6 females).  Subject characteristics, displayed as mean ± SEM (range) were as follows: age 
was 23 ± 1 year (20-32 years); body weight was 72 ± 3 kg (53-94 kg); and body mass index 
(BMI) was 24 ± 1 kg/m² (20-27 kg/m²).  Of the 14 subjects, 2 were Asian and 12 were 
white.  Subjects gave informed consent and the study was approved by the Institutional 
Review Board Human Subjects Committee at The Ohio State University (see appendix). 
 
Treatments 
 There were a total of 2 test meals in this protocol (treatment and control) and they 
were administered in random order.  Each test meal was preceded by a standardized 
dinner the night before, which was followed by an overnight (at least 10 h) fast.   The 
standardized dinner consisted of one can of Ensure plus a variable number of Zone 
Perfect bars such that 1/3 of the subject’s estimated energy expenditure was met.  Energy 
expenditure was based on the Harris Benedict equation multiplied by 1.3 to account for 
very light physical activity (39).    This meal was consumed between 1600 and 1900 h on 
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the night before the test meal and no additional foods were consumed.  The subject began 
the overnight fast following consumption of the standardized dinner.   
 The morning following the fasting period, at approximately 0700 h, subjects 
reported to the laboratory (Room 219, Campbell Hall). Their weight was recorded and 
they rested for 30 minutes.  After the 30 minute rest period, the blood pressure and 
temperature was recorded for each subject and his/her baseline blood samples (1-2 mL) 
was collected via capillary finger-stick (baseline sample).  Immediately following this 
sampling, subjects proceeded to the kitchen area (Room 215 Campbell Hall) and were fed 
the test meal.  The timing for subsequent blood samples began with the first bite of the 
test meal.  The test meals consisted of 8 fl. oz. (240 mL) of a beverage plus spaghetti.  
The beverages were unsweetened, instant decaffeinated tea (the control) or unsweetened, 
instant decaffeinated tea plus 480 mg S. oblonga extract (the treatment).  The spaghetti 
(constant for each meal) consisted of 1 cup (2 servings) Meijer all natural meatless 
spaghetti sauce and 4 ounces (dry weight, 2 servings) Meijer 100% durum semolina 
spaghetti noodles.  This meal provided approximately 106 g carbohydrate, 4 g fat, and 18 
g protein.   
 Subjects resumed fasting after eating the test meal (preferably within 10 min) and 
then blood samples were collected from the subjects via the capillary finger-prick 
technique at 15, 30, 45, 60, 90, and 120 min postprandial (40) (Figure 4).   The subjects 
completed ratings of perceived hunger and symptom record forms at each of the blood 
sampling interval time points.  Subjects completed the rectal gas passage form at hourly 
intervals starting at 60 min postprandial.  The subjects then waited in the laboratory for 
an additional hour after the last blood sample was collected.  At the completion of that 
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hour, the subject completed the hunger, gas passage, and symptom record forms again 
and were fed a lunch that was to be consumed on site.  The contents of the lunch were the 
same as for the standardized dinner the night before the test.  Upon finishing the lunch, 
the subjects were free to leave the laboratory and completed further hunger and symptom 
record forms at hourly intervals for the next 5 hours.  During that 5-hour period, the 
subjects were not allowed to consume additional foods except for water.  After 
completing the last symptom and hunger rating questionnaires, the subjects were allowed 
to resume their normal diet and activity patterns.  The two meal test visits to the 
laboratory were separated by a minimum of 4 days. 
 
Figure 4: Data collection time points; all times refer to the beginning of the test meal 
 
Data Time (min) 
 0 15 30 45 60 90 120 180* 240 300 360 420 480 
Blood Sample X X X X X X X       
Satiety Rating 
Scale X X X X X X X X X X X X X 
Rectal Gas 
Passage     X  X X X X X X X 
Gastrointestinal 
Tolerance  X    X  X X X X X X X 
*Time of Standardized Lunch 
 
ANALYSES 
Serum analysis   
 The whole blood samples (approximately 1-2 mL) were collected in serum 
separator tubes (BD Vacutainer, Becton Dickinson Scientific, Franklin Lakes, NJ) and 
allowed to clot for 5-10 min after collection.  Samples were then centrifuged at 1168 X g 
to obtain serum and the serum was frozen at -20° C until analysis.  Serum glucose and 
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lactate concentrations were determined in duplicate using the YSI 2700 Select Plus 
Biochemistry Analyzer.  This instrument employs the glucose oxidase method and is 
often used in clinical studies as a “gold standard” for comparison with other methods 
(41).   
The positive incremental areas under curve (AUC) for the serum glucose and 
serum lactate responses (0-120 min) were calculated using the method of Wolever et al 
(40).  Briefly, the trapezoidal rule was used to calculate all the area between the subject’s 
postprandial curve and that subject’s baseline serum glucose or serum lactate value (any 
area below the baseline was discarded).  In addition, the baseline-adjusted peaks for 
glucose and lactate (highest value minus the baseline value at time 0) and the excursions 
(highest value minus lowest value) were calculated. 
 
Symptom ratings 
 At the intervals listed in Figure 4, subjects self-rated their perceived levels of 
severity for symptoms of nausea, headache, abdominal cramping, bloating/excessive 
fullness, and flatulence on a ranked scale with the following definitions: 0 indicates no 
symptoms, 1 indicates slight symptoms, 2 indicates mild symptoms, 3 indicates moderate 
symptoms, 4 indicates moderately severe symptoms, and 5 indicates severe symptoms 
(refer to appendix, 42).  Data was presented as the sum of the ratings for hours 1 to 8.  
Thus, the maximum possible symptom score was 40 for each symptom (a rating of 5 
every hour for 8 hours).  For determination of flatus frequency, subjects counted the 
number of rectal gas passages at hourly intervals over the 8-hour period (refer to 
appendix).  A hand-tally counting device (VWR Scientific, West Chester, PA) and a form 
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(see appendix) for recording the results was provided to the subjects to assist in obtaining 
these counts. These data were also presented as the sum of hours 1 to 8.   
 
Hunger ratings 
 A 7-point, equilateral scale (Figure 5) was used to assess hunger of the subjects at 
each of the time points listed in Figure 4 (refer to appendix).  The horizontal distance 
from the left side of the figure was measured and the data from these measurements was 
used to generate an average sum.  This use of this scale to calculate a “satiety index” of 
foods has been validated against measured food intake at 120 min postprandial in a 
previous study (43). 
 
 
Figure 5: Equilateral satiety rating scale (43) 
______________________________________________________________________ 
      1     2 3 4 5                    6                7 
 
extremely            hungry               semi                        no                      semi                 satisfied       extremely      
hungry                                        hungry                  particular              satisfied                   full                                         
                                                                                  feeling 
 
 
Statistical Analyses     
Descriptive statistics were calculated and normality tests were performed for all 
variables using SYSTAT. ANOVA for a randomized block design (subjects as the 
random factor and test food as the fixed factor) was used to test for overall significant 
differences among plasma glucose and plasma lactate treatment means for AUC, peak, 
and individual time points (44). Data were reported as mean ± standard error of the mean, 
and significance was determined at P < 0.05. For gastrointestinal tolerance factors and 
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satiety ratings, randomized block ANOVA was used to compare the total rating for each 
factor between the different treatments. For the flatulence symptom ratings and number 
of gas passages, randomized block ANOVA was used to compare the total rating at each 
time point between the different treatments (44). 
 
RESULTS 
Serum Glucose Response
 Results of the serum glucose response through 120 minutes postprandial to the 
control and treatment meals are shown in Figure 6.  There were no significant differences 
between the fasting serum glucose concentration between the control and treatment meals 
(P = 0.451).  Both meals produced a peak in serum glucose concentration at 30 minutes 
postprandial, with the control peak (7.57 ± 0.24 mmol/dl) being significantly higher than 
the treatment peak (6.88 ± 0.18 mmol/dl, P = 0.005).  An additional reactive 
hyperglycemic peak occurred at 120 minutes postprandial (5.82 ± 0.13 mmol/dl) in the 
control while no peak occurred in the treatment (5.40 ± 0.10 mmol/dl, P = 0.001).   
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Figure 6: Postprandial Serum Glucose Response 
 
Postprandial Serum Glucose Response
4
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 *Denotes significant difference between treatment and control meals (P < 0.05) 
 
Time Postprandial Control mean       
[serum glucose] 
mmol/dl¹ 
Treatment mean   
[serum glucose] 
mmol/dl¹ 
P Level   
(Significance at P < 
0.05)  
0 5.09 ± 0.10 5.16 ± 0.14 0.451 NS 
15 6.33 ± 0.17 6.41 ± 0.16 0.550 NS 
30 7.57 ± 0.24 6.88 ± 0.18 0.005 S 
45 6.65 ± 0.25 6.40 ± 0.19 0.324 NS 
60 5.77 ± 0.20 5.67 ± 0.20 0.683 NS 
90 5.52 ± 0.10 5.43 ± 0.15 0.523 NS 
120 5.82 ± 0.13 5.40 ± 0.10 0.001 S 
¹Mean ± standard error of the mean (SEM), number of subjects = 14  
  S = Significant (P < 0.05), NS = Nonsignificant 
 
 
 Results of the mean serum glucose baseline-adjusted peak (BAP) and excursion 
of the control and treatment meals are shown in Figure 7.  The mean BAP between the 
control meal (2.52 ± 0.24 mmol/dl) and the treatment meal (1.84 ± 0.16 mmol/dl) were 
significantly different (P < 0.001).  Additionally, the mean excursion of the control (2.54 
± 0.24 mmol/dl) and the treatment (1.95 ± 0.14 mmol/dl) were significantly different (P = 
0.002). 
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Figure 7:  Serum Glucose Baseline Adjusted Peak and Excursion (Maximum-                                          
Minimum) Data 
 
 Control        
[serum glucose] 
mmol/dl¹ 
Treatment  
[serum glucose] 
mmol/dl¹ 
P Level   
(Significance at P < 
0.05)  
Baseline 5.09 ± 0.10 5.16 ± 0.14 0.451 NS 
Maximum 7.62 ± 0.24 7.00 ± 0.17 0.004 S 
Minimum 5.08 ± 0.10 5.05 ± 0.11 0.653 NS 
BAP 2.52 ± 0.24 1.84 ± 0.16 < 0.001 S 
Excursion 2.54 ± 0.24 1.95 ± 0.14 0.002 S 
¹Mean ± standard error of the mean (SEM), number of subjects = 14 
  S = Significant (P < 0.05), NS = Nonsignificant 
 
Serum Lactate Response 
 Results of the serum lactate response through 120 minutes postprandial to the 
control and treatment meals are shown in Figure 8.  There were no significant differences 
between the fasting serum lactate concentration between the control and treatment meals 
(P = 0.298).  Both meals produced a peak in serum lactate concentration between 30 and 
60 minutes postprandial, with the control peak (2.39 ± 0.33 mmol/dl) occurring at 60 
minutes postprandial and the treatment peak (2.00 ± 0.18 mmol/dl) occurring at 30 
minutes postprandial.  The peaks in serum lactate concentration were not significantly 
different in the control versus the treatment meal (P = 0.134).  At 90 minutes 
postprandial, the mean control serum lactate concentration (1.71 ± 0.09 mmol/dl) 
significantly differed from the mean treatment serum lactate concentration (1.48 ± 0.09 
mmol/dl, P = 0.011). 
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Figure 8: Postprandial Serum Lactate Response 
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Time Postprandial Control mean       
[serum lactate] 
mmol/dl¹ 
Treatment mean   
[serum lactate] 
mmol/dl¹ 
P Level   
(Significance at P < 
0.05)  
0 1.39 ± 0.14 1.29 ± 0.10 0.298 NS 
15 1.64 ± 0.13 1.61 ± 0.13 0.890 NS 
30 2.02 ± 0.12 2.00 ± 0.18 0.888 NS 
45 2.28 ± 0.14 1.99 ± 0.20 0.084 NS 
60 2.39 ± 0.33 1.72 ± 0.09 0.075 NS 
90 1.71 ± 0.09 1.48 ± 0.09 0.011 S 
120 1.57 ± 0.08 1.48 ± 0.11 0.300 NS 
¹Mean ± standard error of the mean (SEM), number of subjects = 14 
  S = Significant (P < 0.05), NS = Nonsignificant 
 
 Results of the mean serum lactate baseline-adjusted peak (BAP) and excursion of 
the control and treatment meals are shown in Figure 9.  The mean BAP between the 
control meal (1.26 ± 0.24 mmol/dl) and the treatment meal (1.01 ± 0.16 mmol/dl) were 
not significantly different (P = 0.249).  Additionally, the mean excursion of the control 
(1.40 ± 0.29 mmol/dl) and the treatment (1.10 ± 0.19 mmol/dl) were not significantly 
different (P = 0.201). 
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Figure 9:  Serum Lactate Baseline Adjusted Peak and Excursion (Maximum-
Minimum) Data 
 
 Control  
[serum lactate] 
mmol/dl¹ 
Treatment  
[serum lactate] 
mmol/dl¹ 
P Level   
(Significance at P < 
0.05)  
Baseline 1.39 ± 0.14 1.29 ± 0.10 0.298 NS 
Maximum 2.65 ± 0.32 2.29 ± 0.22 0.134 NS 
Minimum 1.24 ± 0.08 1.19 ± 0.06 0.478 NS 
BAP 1.26 ± 0.24 1.01 ± 0.16 0.249 NS 
Excursion 1.40 ± 0.29 1.10 ± 0.19 0.201 NS 
¹Mean ± standard error of the mean (SEM), number of subjects = 14 
  S = Significant (P < 0.05), NS = Nonsignificant 
 
 
Positive Incremental AUC 
Results of the positive incremental AUC serum glucose and lactate responses for 
both the control and treatment meals are shown in Figure 10.  The mean serum glucose 
AUC showed a significant 25% reduction (P = 0.022) in postprandial glycemia between 
the treatment meal (AUC = 88.3 ± 11.0) and the control meal (AUC = 118.4 ± 14.0).  The 
mean serum lactate AUC also displayed a significant 29% reduction (P = 0.033) in 
postprandial lactate response between the treatment meal (AUC = 47.6 ± 6.9) and the 
control meal (AUC = 67.4 ± 10.2).  
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Figure 10: Mean Serum Glucose and Lactate AUC 
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Symptom Responses
 Figure 11 displays the mean sum of the symptom responses for the control and 
treatment meals from hours 0 through 8.   The maximum response for nausea, headache, 
abdominal cramping, bloating/excessive fullness, and flatulence was 40 (a recording of 5 
through the full 8 hours).  The maximum response for satiety was 91 (a baseline 
recording of 7 followed by a recording of 7 through the full 8 hours at the specified time 
points).  The symptoms of nausea (P = 0.175), headache (P = 0.646), abdominal 
cramping (P = 0.729), bloating/excessive fullness (P = 0.811), and satiety (P = 0.953) did 
not differ significantly between the control meal and the treatment meal.  The symptom 
of flatulence (P = 0.002), however, differed significantly with the mean sum of the 
control responses being 2.50 ± 0.86 and the mean sum of the treatment responses being 
9.36 ± 2.69. 
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Figure 11: Mean Symptom Response Sum (Hours 0-8) 
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Symptom Mean Control 
Response¹ 
Mean Treatment 
Response¹ 
P Level   
(Significance at P < 
0.05) 
Nausea² 0.29 ± 0.19 1.93 ± 1.19 0.175NS 
Headache² 1.21 ± 0.67 1.57 ± 0.88 0.646 NS 
Abdominal 
Cramping² 
2.07 ± 1.77 1.57 ± 0.86 0.729 NS 
Bloating/ Excessive 
Fullness² 
1.64 ± 1.49 1.36 ± 0.68 0.811 NS 
Flatulence² 2.50 ± 0.86 9.36 ± 1.77 0.002 S 
Satiety³ 59.2 ± 2.93 59.4 ± 2.69 0.953 NS 
¹Mean ± standard error of the mean (SEM), number of subjects = 14 
  S = Significant (P < 0.05), NS = Nonsignificant 
²The maximum possible sum for perceived symptom severity was 40 (a rating of 5 for each hour) 
³The maximum possible sum for perceived satiety was 91 (a rating of 7 for each time point) 
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Flatulence Data 
 Figures 12 and 13 display the mean flatulence symptom ratings along with the 
total number of rectal gas passages recorded at each hourly interval from hours 0 to 8 for 
the control and treatment meals.  The maximum mean flatulence symptom rating is 5.  
The mean flatulence symptom ratings for the control and treatment meals differed 
significantly at hours 4 (P = 0.001), 5 (P = 0.022), 6 (P = 0.006), and 7 (P = 0.001).  The 
number of rectal gas passages differed significantly between the control and treatment 
meals at the time intervals of 3-4 hours (P = 0.001), 4-5 hours (P = 0.015), 5-6 hours (P = 
0.004), and 6-7 hours (P = 0.001).  The total rectal gas passage mean also differed 
significantly between the two meals (P = 0.001).  Figure 14 displays the direct positive 
relationship (R² = 0.8658) between the number of gas passages recorded with the 
perceived severity of flatulence symptoms.  
 
Figure 12: Mean Flatulence Symptom Rating at Baseline and at Each Hourly 
Interval Postprandial 
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Time              
(Hour Postprandial) 
Control¹²          Treatment¹       P Level   
(Significance at P<0.05) 
0 0.07 ± 0.07 0.07 ± 0.07 1.00 NS 
1 0.21 ± 0.11 0.43 ± 0.23 0.426 NS 
2 0.21 ± 0.11 0.29 ± 0.16 0.671 NS 
3 0.29 ± 0.13 0.79 ± 0.28 0.110 NS 
4 0.29 ± 0.22 1.71 ± 0.40 0.001 S 
5 0.43 ± 0.17 1.50 ± 0.43 0.022 S 
6 0.29 ± 0.13 1.50 ± 0.36 0.006 S 
7 0.21 ± 0.11 1.71 ± 0.34 0.001 S 
8 0.57 ± 0.36 1.43 ± 0.36 0.152 NS 
¹Mean ± standard error of the mean (SEM), number of subjects = 14 
  S = Significant (P < 0.05), NS = Nonsignificant 
²The maximum possible score for the perceived flatulence symptom rating was 5 
 
 
 
 
Figure 13: Number of Gas Passages 
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Time              
(Hour Postprandial) 
Control¹            Treatment¹       P Level   
(Significance at P < .05) 
0-1 0.29 ± 0.16 0.57 ± 0.17 0.104 NS 
1-2 0.71 ± 0.32 1.00 ± 0.33 0.525 NS 
2-3 0.79 ± 0.21 1.43 ± 0.39 0.156 NS 
3-4 1.29 ± 0.50 4.29 ± 0.87 0.001 S 
4-5 1.14 ± 0.46 4.57 ± 1.45 0.015 S 
5-6 0.64 ± 0.27 4.14 ± 0.98 0.004 S 
6-7 0.93 ± 0.31 5.07 ± 0.92 0.001 S 
7-8 1.50 ± 0.69 5.29 ± 1.49 0.050 NS 
Total 7.29 ± 1.76 26.4 ± 4.59 0.001 S 
¹Mean ± standard error of the mean (SEM), number of subjects = 14 
  S = Significant (P < 0.05), NS = Nonsignificant 
 
 
Figure 14: Relationship Between Number of Gas Passages and Perceived Symptoms 
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DISCUSSION 
 
 As the prevalence of T2DM and the associated costs in dealing with the induced 
complications of T2DM rises, it is becoming increasingly important to find alternative 
ways to prevent progression of impaired glucose tolerance into T2DM, delay the 
progression of those with T2DM, and also treat complications brought about by T2DM.  
The alpha-glucosidase inhibitor acarbose has been shown in a chronic study to reduce the 
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risk of progression from impaired glucose tolerance to diabetes by 25% (15).  Acarbose 
has also been shown to reduce the risk of myocardial infarctions and other cardiovascular 
events in a meta-analysis (17).  Patients using acarbose had reduced HbA1c levels, 
reduced fasting and postprandial blood glucose levels, reduced plasma triglyceride levels, 
reduced body weight and BMI, reduced systolic blood pressure, and reduced insulin 
levels (17). 
 In this study, the effects of the alpha-glucosidase inhibitors in S. oblonga extract, 
salacinol and kotalanol, on a solid, high starch meal were measured.  Previous studies 
have demonstrated the effectiveness of S. oblonga extract on lowering postprandial 
glycemia to a liquid nutritional supplement containing 61% maltodextrin (13, 27).  This 
study supports those findings, with an observed 25% reduction in positive incremental 
AUC (P = 0.022) being approximately equal to the 23% reduction of Heacock et al. and 
the 24% reduction of Collene et al.  This result, however, does not support the increased 
anti-hyperglycemic effects to a solid meal versus a liquid meal observed with acarbose 
(34).  A possible reason for this similar effectiveness to both liquid and solid meals is that 
the S. oblonga extract does not need the delayed gastric emptying offered by a solid meal 
for full alpha-glucosidase activity. 
 In addition to a reduced positive incremental AUC for serum glucose to the 
treatment meal, the peak serum glucose concentration was reduced by 8% (P = 0.006) 
and the 120 min serum glucose concentration was reduced by 7% (P = 0.001) in the 
treatment meal.  These results also support the glucose-attenuating effects of S. oblonga 
extract found in previous studies.  The decreased peak glucose concentration indicates 
that the alpha-glucosidase activity of salacinol and kotalanol inhibited full digestion and 
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absorption of the starch meal.  The decreased peak also indicates that S. oblonga extract 
may reduce many of the complications of T2DM that occurred when the peak glucose 
concentrations decreased in studies with acarbose.  The decrease in glucose concentration 
occurring at 120 min postprandial indicates that the S. oblonga extract prevented the mild 
reactive hypoglycemic event which occurred in the control meal.  This effect is most 
likely related to the decrease in peak blood glucose in the treatment meal. 
  The positive incremental AUC serum lactate response also decreased by 29% (P 
= 0.033) in the treatment meal compared with the control meal.  To the author’s 
knowledge, no previous studies have been conducted relating the postprandial glycemic 
and lactate responses to each other.  The decreased in serum lactate AUC is hypothesized 
to have occurred because of the decreased postprandial glucose load arriving to the liver, 
indicated by the reduction in serum glucose AUC.  With a decreased glucose load, less 
glucose was available for use in metabolism creating a reduction in circulating lactate, a 
metabolite of glucose.  The shape of the serum lactate concentration curve (Figure 8) 
supports this hypothesis.  The peak in serum lactate concentration occurred between 30 
and 60 minutes postprandial, compared with the peak serum glucose concentration 
occurring at 30 minutes postprandial.  The delay in the lactate peak indicates the time 
required for the circulating glucose to be metabolized by cells, releasing lactate into 
circulation. 
 Decreases in the serum lactate concentrations of 13% (P = 0.084) and 28% (P = 
0.075) were observed at 45 and 60 minutes postprandial, although these decreases were 
not significant.  A significant 13% decrease (P = 0.011) was observed at 90 minutes 
postprandial, however.  These reductions over a broad range of time indicate that S. 
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oblonga extract may have longer-term control of serum lactate levels via a reduced 
postprandial glycemic response.  These findings may have significance in exercise 
science for athletes wishing to attenuate their blood glucose levels and minimize 
circulating lactate levels as well, although further studies need to be conducted to 
determine S. oblonga extract’s effect on athletic performance. 
 The baseline adjusted peak and the excursion data showed significant differences 
for serum glucose concentrations but insignificant differences for serum lactate 
concentrations.  Serum glucose BAP decreased 27% (P < 0.001) and the excursion 
decreased 23% for the treatment meals compared with the control meals.  Despite similar 
AUC reductions for both glucose and lactate, the BAP and excursion data indicate that 
the postprandial glycemic responses provide a better indication of the possible anti-
diabetic effects of S. oblonga.  This supports the literature documenting the correlation 
between lowering postprandial glycemia and reducing complications associated with 
T2DM. 
 No significant differences were found with nausea (P = 0.175), headache (P = 
0.646), or abdominal cramping (P = 0.729) symptoms between the treatment and the 
control meals.  These findings support those of Heacock et al.  However, Heacock et al. 
also found an increased perceived symptom of bloating/excessive fullness in the S. 
oblonga treatment.  In this study, no significant difference in bloating/excessive fullness 
symptoms were observed (P = 0.811).  This discrepancy may have occurred due to the 
use of a solid meal in this study rather than a liquid meal used by Heacock et al.  The 
delayed gastric emptying from the solid meal may have led to a slower rate of entry of 
undigested carbohydrate into the large intestine as well, rather than the appearance of a 
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large bolus of undigested carbohydrate from a liquid meal.  A slower, yet more constant 
rate of fermentation of the carbohydrate by colonic microflora may have led to a 
decreased perception of bloating and excessive fullness.  Additionally, there were no 
significant differences in satiety (P = 0.953) between the treatment and control meals. 
 Consistent with the findings of Heacock et al. and Collene et al., the perceived 
flatulence symptoms in this study were significantly greater (P = 0.002) in the treatment 
meals compared with the control meals.  Specifically, at hours 4 (P = 0.001), 5 (P = 
0.022), 6 (P = 0.006), and 7 (P = 0.001) postprandial the perceived flatulence symptoms 
were significantly greater in the treatment.  Additionally, the total number of rectal gas 
passages was significantly greater (P = 0.001) in the treatment compared with the control.  
During the time periods of 3-4 hours (P = 0.001), 4-5 hours (P = 0.015), 5-6 hours (P = 
0.004), and 6-7 hours (P = 0.001) postprandial, there was a significant increase in the 
recorded number of gas passages to the treatment meal compared with the control meal.  
These data support the alpha-glucosidase effects of salacinol and kotalanol documented 
in the literature.  The increased amount of flatulence occurring approximately 4 hours 
postprandial indicate that undigested carbohydrate from the solid meal was being 
fermented by the colonic microflora to produce gaseous byproducts.  The 8 hour 
postprandial time point data shows an increase in perceived flatulence (P = 0.152) and 
the number of gas passages (P = 0.050), however this increase is not significant.   
 Plotting the total number of gas passages versus the perceived flatulence symptom 
ratings (Figure 14) showed a strong, positive linear correlation between the two (R² = 
0.8658).  This result verifies the use of subjective flatulence symptom perception rating 
forms to approximate the objective data of number of rectal gas passages.  Future studies 
 33
should focus on the perceived flatulence symptom data, not only because it approximates 
the number of gas passages, but also because perceived symptoms by the subject is more 
important in the likelihood of use of S. oblonga extract as part of a treatment plan for 
diabetes. 
Conclusion
 A limitation of this study is the use of a small sample size (N = 14).  Several of 
the subjects’ postprandial glucose concentrations were unresponsive to the S. oblonga 
extract.  There may be an unresponsive subgroup in the population, however the only 
way to determine this is to include a greater sample size.  Time and funding limitations 
prevented measuring a possible carryover effect of the S. oblonga extract on postprandial 
glycemia to the standardized lunch.  A residual amount of the extract may lower the 
response to a subsequent meal, compounding the anti-hyperglycemic effects.  Another 
additional limitation caused by time and funding was the use of the number of gas 
passages and perceived flatulence symptoms to measure the degree of colonic 
fermentation.  Previous studies by Heacock et al. and Collene et al. have measured breath 
hydrogen excretions as a more objective quantitative measurement for colonic microflora 
fermentation. 
 Future studies using S. oblonga extract can measure its effects on other sources of 
carbohydrates for the solid meal.  Other studies can measure the effects of chronic use of 
the extract with type 2 diabetic and impaired glucose tolerance populations on diabetic 
complications and prevention of progression into T2DM.  Chronic use studies of the 
extract can measure its effects on HbA1c concentrations in those subjects with T2DM as 
well.  Similar studies have already been done using the prescription drug acarbose.  Other 
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studies can measure a dosage effect of S. oblonga extract on postprandial glycemia to a 
solid meal.  Heacock et al. measured the dosage effect of the extract using a liquid 
nutritional supplement; however no studies have been done using a solid meal.  
Additional studies measuring S. oblonga extract on exercise in athletes can also be 
conducted.  There may be possible athletic implications to the lowered lactate response to 
the treatment meal.   
 In conclusion, S. oblonga extract lowered the postprandial glucose response by 
25% (P = 0.022) and the postprandial lactate response by 29% (P = 0.033).  The extract 
did not cause any significant differences in perceived nausea, headache, abdominal 
cramping, bloating/excessive fullness, or satiety.  However, S. oblonga extract did cause 
an increase in perceived flatulence (P = 0.002) and in total number of rectal gas passages 
(P = 0.001), indicating the alpha-glucosidase activity of the extract.  Despite the small 
sample size of the study (N = 14), these results can be used to support the use of S. 
oblonga extract in treating those with T2DM or with impaired glucose tolerance.  Future 
studies can determine how to most effectively use S. oblonga extract as an alpha-
glucosidase inhibitor. 
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APPENDICES 
Test Visit Sequence of Events 
 
 
 
Diagram of the sequence of events for each meal 
test visit 
Standardized 
Dinner 
30 min 
Rest 
period 
Overnight 
fasting 
0   15  30   45   60  
                           
90 120            180 
 
         time  
 points (min)   
240 300 360 
   
420 480 
Test meal  
and beverage 
Standardized lunch meal 
(same as standardized 
dinner).  Subject leaves lab 
when meal is finished. 
Blood samples 
Baseline (just prior to time 0), 15, 30, 45, 60, 90, 120 min
Hunger ratings 
0, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, 480 min
Subject stays in laboratory
 (219 Campbell) 
Subject completes records 
at home or off-site 
Symptom ratings 
0, 60, 120, 180, 240, 300, 360, 420, 480 min
*NOTE:  ALL TIMINGS PERTAIN TO  
THE START OF THE TEST MEAL (SPAGHETTI AND BEVERAGE) 
Collection of data on frequency  
Of rectal gas passages (8 intervals)
0-60 min 
60-120 min 
120-180 min 
180-240 min 
240-300 min 
300-360 min 
360-420 min 
420-480 min 
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Symptom Ratings Scale
Symptom ratings 
 
 
 
Date     : 
Subject  # : 
Subject initials: 
Treatment visit # : 
Timepoint : 
 
 
 
For each timepoint listed below, please describe how you feel for each of the symptoms 
listed.  Use the following scale to rate your experience of the symptoms listed in the 
table: 
 
0   -   No Symptoms 
1   -   Slight Symptoms 
2   -   Mild Symptoms 
3   -   Moderate Symptoms 
4   -   Moderately Severe Symptoms 
5   -   Severe Symptoms 
 
 
 
Timepoint Nausea Headache Abdominal 
Cramping 
Bloating/Excessive 
Fullness 
Flatulence 
(gas) 
0 hr      
      
1 hr      
      
2 hr      
      
3 hr      
      
4 hr      
      
5 hr      
      
6 hr      
      
7 hr      
      
8 hr      
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Rectal Gas Passages Form 
 
 
Rectal Gas Passages Data Collection Form 
 
 
 
Date     : 
Subject  # : 
Subject initials: 
Treatment visit # : 
Timepoint : 
 
 
 
For each interval listed below, record the number of rectal gas passages listed on the 
counter device that was provided.  If a passage occurs exactly on the hour, include it in 
the next interval (or don’t count it if it occurs exactly on the 8 hour time point). 
 
 
 
Timepoint Number of Rectal Gas 
Passages 
From 0-1 hr after the test meal  
  
From 1-2 hrs after the test meal  
  
From 2-3 hrs after the test meal  
  
From 3-4 hours after the test meal  
  
From 4-5 hours after the test meal  
  
From 5-6 hours after the test meal  
  
From 6-7 hours after the test meal  
  
From 7-8 hours after the test meal  
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Satiety Form 
 
                                                      Hunger Rating Scale 
 
Date     : 
Subject  # : 
Subject initials: 
Treatment visit # : 
 
Please indicate by a slash or single stroke through the line, the level of hunger/satiety 
experienced at each of the timepoints mentioned below: 
 
 
Timepoint   0 minutes 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
 
 
Timepoint   15 minutes 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
 
 
Timepoint    30 minutes 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
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Timepoint   45 minutes 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
Timepoint   60 minutes (1 hour) 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                    
                                                                                     feeling 
 
 
Timepoint   90 minutes (1.5 hours) 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
 
 
Timepoint   120 minutes (2 hours) 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
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Timepoint   180 minutes (3 hours) 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
 
 
Timepoint   240 minutes (4 hours) 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
 
 
 
Timepoint   300 minutes (5 hours) 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
 
 
Timepoint   360 minutes (6 hours) 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
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Timepoint   420 minutes (7 hours) 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                    
                                                                                     feeling 
 
 
Timepoint   480 minutes (8 hours) 
 
________________________________________________________________________
_ 
1 2 3 4 5 6 7 
 
extremely            hungry            semi                           no                      semi                        satisfied       
extremely         
hungry                                        hungry                      particular          satisfied                        full                                     
                                                                                     feeling 
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